Walvax Biotechnology Co Ltd
SZSE:300142
Intrinsic Value
Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. [ Read More ]
The intrinsic value of one Walvax Biotechnology Co Ltd stock under the Base Case scenario is 23.65 CNY. Compared to the current market price of 14.33 CNY, Walvax Biotechnology Co Ltd is Undervalued by 39%.
Valuation Backtest
Walvax Biotechnology Co Ltd
Run backtest to discover the historical profit from buying and selling Walvax Biotechnology Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Walvax Biotechnology Co Ltd
| Current Assets | 8.7B |
| Cash & Short-Term Investments | 4.4B |
| Receivables | 3.3B |
| Other Current Assets | 1.1B |
| Non-Current Assets | 6.9B |
| Long-Term Investments | 1.1B |
| PP&E | 4B |
| Intangibles | 1.5B |
| Other Non-Current Assets | 241.3m |
| Current Liabilities | 3.2B |
| Accounts Payable | 1.8B |
| Accrued Liabilities | 878.2m |
| Short-Term Debt | 352.9m |
| Other Current Liabilities | 200.3m |
| Non-Current Liabilities | 3B |
| Long-Term Debt | 455.5m |
| Other Non-Current Liabilities | 2.6B |
Earnings Waterfall
Walvax Biotechnology Co Ltd
|
Revenue
|
4.1B
CNY
|
|
Cost of Revenue
|
-749.4m
CNY
|
|
Gross Profit
|
3.4B
CNY
|
|
Operating Expenses
|
-2.6B
CNY
|
|
Operating Income
|
771.7m
CNY
|
|
Other Expenses
|
-352.3m
CNY
|
|
Net Income
|
419.4m
CNY
|
Free Cash Flow Analysis
Walvax Biotechnology Co Ltd
Profitability Score
Profitability Due Diligence
Walvax Biotechnology Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Walvax Biotechnology Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Walvax Biotechnology Co Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Walvax Biotechnology Co Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Walvax Biotechnology Co Ltd
According to Wall Street analysts, the average 1-year price target for Walvax Biotechnology Co Ltd is 22.44 CNY with a low forecast of 19.19 CNY and a high forecast of 26.25 CNY.
Shareholder Return
Price
Walvax Biotechnology Co Ltd
| Average Annual Return | 14.34% |
| Standard Deviation of Annual Returns | 30.19% |
| Max Drawdown | -85% |
| Market Capitalization | 22.9B CNY |
| Shares Outstanding | 1 607 350 016 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan and currently employs 1,866 full-time employees. The company went IPO on 2010-11-12. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The firm distributes its products mainly in domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one Walvax Biotechnology Co Ltd stock under the Base Case scenario is 23.65 CNY.
Compared to the current market price of 14.33 CNY, Walvax Biotechnology Co Ltd is Undervalued by 39%.
You don't have any saved screeners yet
